Biomedicine Group Journals List:
Biomedicine has been a powerful
model and had a tremendously significant influence in individuals' understandings of wellbeing and sickness and (maybe for a lion's share of individuals in the UK today) their consistence with the system that underpins biomedicine. Defenders of
biomedicine propose that it remains with numerous fabulous achievements: the decrease of high death rates, for example, those found in adolescence in the previous piece of the twentieth century, and the annihilation of a portion of the significant executioners, for example, smallpox, polio and so forth. Be that as it may, a restricting contention has been advanced that mortality has been drastically diminished during the previous century due to improved lodging and working conditions and especially improved sustenance, instead of in light of a specific preventive or biomedical measure, for example, inoculation or the across the board utilization of anti-toxins. While biomedical talk will in general concentrate on clinical advances and mediations at an individual level, others may wish to accentuate joins between the complete condition and wellbeing. Germ hypothesis and lab science stay significant today as specialists depend increasingly more on research centre testing to assist them with diagnosing and screen explicit conditions or infections. In any case, explicit etiology (that is, the equivalent miniaturized scale life form causing a similar disease) turned out to be progressively open to address by the mid-twentieth century as logical exploration uncovered the hugeness of co-factors, have state, just as attacking creature. During the 1970s Engel required 'another clinical model' which stressed multi-causality. Examination into AIDS, for instance, has created hypotheses which accentuate different causes.
High Impact List of Articles
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
Clinical rationale of sucroferric oxyhydroxide for controlling hyperphosphatemia in patients with chronic kidney disease
Stuart M Sprague, Morgan Marcuccilli & Viatcheslav Rakov
Drug Evaluation: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
David W Morris
Editorial: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
Research in acute decompensated heart failure: challenges and opportunities
Brian C Hiestand
Clinical Trail Outcomes: Clinical Investigation
-
New considerations in the design of clinical trials for amyotrophic lateral sclerosis
James D Berry, Merit E Cudkowicz
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for amyotrophic lateral sclerosis
James D Berry, Merit E Cudkowicz
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for amyotrophic lateral sclerosis
James D Berry, Merit E Cudkowicz
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for amyotrophic lateral sclerosis
James D Berry, Merit E Cudkowicz
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for amyotrophic lateral sclerosis
James D Berry, Merit E Cudkowicz
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for amyotrophic lateral sclerosis
James D Berry, Merit E Cudkowicz
Review Article: Clinical Investigation
Relevant Topics in Clinical